Swiss study shows 60% of migrant HIV diagnoses are made post-arrival, challenging assumptions about when infections actually ...
There were still 32,000 new cases of HIV in the U.S. in 2022. And about thousands of people still die annually from AIDS. HIV ...
Lenacapavir is a revolutionary long-acting injectable drug that offers six months of protection with just two annual ...
ScienceAlert on MSN
HIV's Cunning Strategy For Hiding in Our Body Finally Revealed
According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...
South Africa has become the first African country, and our medicines regulator the third worldwide, to register the ...
A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more? CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...
The drug, Lenacapavir, is the world's first injectable Pre-Exposure Prophylaxis (PrEP). According to the World Health ...
South Africa has become the first African country – and our medicines regulator the third worldwide – to register the ...
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.
A study of an urban US population reports a sharp decline in dermatologic disease in people with newly diagnosed HIV and ...
The South African Health Products Regulatory Authority has approved Lenacapavir, a long-acting injection that prevents HIV ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback